Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Down Syndrome × Idarubicin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 131 Leukemia 59 Precursor Cell Lymphoblastic Leukemia-Lymphoma 26 Leukemia, Myelomonocytic, Acute 24 Leukemia, Monocytic, Acute 23 Leukemia, Erythroblastic, Acute 21 Leukemia, Megakaryoblastic, Acute 20 Myelodysplastic Syndromes 19 Congenital Abnormalities 18 Leukemia, Promyelocytic, Acute 11 Leukemia, Myelomonocytic, Chronic 10 Anemia, Refractory, with Excess of Blasts 10 Recurrence 8 Myeloproliferative Disorders 7 Leukemia, Myeloid, Chronic-Phase 7 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6 Leukemia, Eosinophilic, Acute 6 Leukemia, Biphenotypic, Acute 6 Lymphoma 5 Leukemia, Basophilic, Acute 5 Carcinoma, Hepatocellular 5 Neoplasm, Residual 4 Multiple Myeloma 4 Blast Crisis 4 Neutropenia 3 Neoplasms, Plasma Cell 3 Lymphoma, Large B-Cell, Diffuse 3 Leukemia, Myeloid, Accelerated Phase 3 Neoplasms 2 Myelodysplastic-Myeloproliferative Diseases 2

Interventions

Cytarabine 3 asparaginase erwinia chrysanthemi recombinant 2 Thioguanine 2 Etoposide 2 Daunorubicin 2 Asparaginase 2 prednylidene 1 pegaspargase 1 merphos 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 deltacortene 1 blinatumomab 1 azathiopurine 1 auricularum 1 Vincristine 1 Radiotherapy 1 Radiation 1 Prednisone 1 Prednisolone 1 N,N-dicyclohexyl-isoborneol-10-sulfonamide 1 Mitoxantrone 1 Methylprednisolone 1 Methotrexate 1 Mercaptopurine 1 Leyk 1 Leucovorin 1 Idarubicin 1 Doxorubicin 1 Dexamethasone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07232134 2025-11-20

AML-DS-2025

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Phase 3 Recruiting

Other hematologic neoplasm

Down Syndrome, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡